Eurekare is a startup that operates in the synthetic biology (SynBio) sector, focusing on health, environment, sustainability, and biomanufacturing. SynBio is a field that combines engineering and computer sciences with biology, aiming to revolutionize various aspects of life, from healthcare to environmental protection. Eurekare's mission is to bring disruptive technologies in these areas to the market.

The company serves a diverse range of clients, including early-stage startups and mature SynBio companies across Europe, the UK, and Israel. It scouts for ambitious SynBio projects and supports the best in the field through pitch competitions, workshops, and conferences. Eurekare also acts as a bridge between academia and industry, financing and developing synthetic biology innovation.

Eurekare's business model is centered around investment. The company is dedicated to investing in projects that use synthetic biology in innovative ways. It supports ventures at different stages of their development to maintain a balanced portfolio. In 2021, Eurekare raised €25 million for its launch and has made nine investments in the health space, including a Special Purpose Acquisition Company (SPAC), a company set up to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company.

In summary, Eurekare is a forward-thinking startup that is leveraging the potential of synthetic biology to address major challenges in health, environment, and sustainability. It operates as an investor, supporting and nurturing SynBio projects and companies across Europe.

Keywords: Synthetic Biology, Health, Environment, Sustainability, Biomanufacturing, Investment, Startups, Pitch Competitions, Academia-Industry Bridge, Special Purpose Acquisition Company.